Expertise in
3
conditions

Rik Joos

ZNA Jan Palfijn
Antwerpen, VLG, BE 
Expertise in
3
conditions
ZNA Jan Palfijn
Antwerpen, VLG, BE 

Overview

Rik Joos practices practicing medicine in Antwerpen, Belgium.

Mr. Joos is highly rated in 3 conditions, according to our data. His clinical expertise encompasses Juvenile Idiopathic Arthritis (JIA), Arthritis, Exogenous Lipoid Pneumonia, and Psoriatic Arthritis.

He is actively involved in clinical research, co-authoring 42 peer reviewed articles and participating in 6 clinical trials.

Gender

Male

Locations

ZNA Jan Palfijn
Antwerpen, VLG, Belgium
Other Locations
Hospital St Jean
Brussels, BRU, Belgium
Gent, VLG, Belgium
UZ Leuven, Vlaams Brabant
Leuven, VLG, Belgium
ZNA Jan Palfijn
Merksem, VLG, Belgium
Ziekenhuis Netwerk Antwerpen
Berchem, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: June 24, 2026
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: November 17, 2025
Intervention Type: Drug
Study Drug: ABX464
Study Phase: Phase 2
Effectiveness of a Combination of Methotrexate and a Step Down Glucocorticoid Regimen (COBRA-Slim) for Remission Induction in Patients With Early Rheumatoid Arthritis (RA), With or Without Fast Access to 24 Weeks of Tumor Necrosis Factor (TNF) Blockade in Insufficient Responders, a Randomized, Multicenter, Pragmatic Trial
Effectiveness of a Combination of Methotrexate and a Step Down Glucocorticoid Regimen (COBRA-Slim) for Remission Induction in Patients With Early Rheumatoid Arthritis (RA), With or Without Fast Access to 24 Weeks of Tumor Necrosis Factor (TNF) Blockade in Insufficient Responders, a Randomized, Multicenter, Pragmatic Trial
Enrollment Status: Completed
Publish Date: June 19, 2025
Intervention Type: Drug
Study Drugs: Etanercept, Leflunomide
Study Phase: Phase 4
Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα
Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα
Enrollment Status: Completed
Publish Date: February 15, 2023
Intervention Type: Drug
Study Drugs: ABX464, Methotrexate
Study Phase: Phase 2
A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Dose Regimens of CC-10004 in Subjects With Active Psoriatic Arthritis
A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Two Dose Regimens of CC-10004 in Subjects With Active Psoriatic Arthritis
Enrollment Status: Completed
Publish Date: June 19, 2020
Intervention Type: Drug
Study Phase: Phase 2
Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)
Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)
Enrollment Status: Completed
Publish Date: September 27, 2019
Intervention Type: Other
View 5 Less Clinical Trials

42 Total Publications

Radiographic progression in psoriatic arthritis: head-to-head comparison of the Ratingen score and the Sharp-van der Heijde method.
Radiographic progression in psoriatic arthritis: head-to-head comparison of the Ratingen score and the Sharp-van der Heijde method.
Journal: Rheumatology (Oxford, England)
Published: March 02, 2026

Frequently Asked Questions about Rik Joos

Is Rik Joos a top-rated expert for Juvenile Idiopathic Arthritis (JIA)?

MediFind is an objective health platform that identifies experts based on real-world data. Rik Joos is classified as an Distinguished expert for Juvenile Idiopathic Arthritis (JIA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Rik Joos participate in research or clinical trials?

Yes. Rik Joos has published 42 articles and abstracts on conditions like Juvenile Idiopathic Arthritis (JIA). You can view a list of Rik Joos's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Joos's expertise for a condition
ConditionClose
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile